CDMO– tag –
-
BIOSECURE Act Reshapes Biopharma Supply Chains, Driving API and Oligo CDMO Expansion in South Korea
CHOSUNBIZ South Korea Overview The U.S. BIOSECURE Act is catalyzing a significant shift in biopharmaceutical supply chains away from China, creating substantial opportunities for South Korean contract development and manufacturing organi... -
South Korean Biotech Giants Diverge: Samsung Biologics Faces Labor Risks Amid Record Growth, Celltrion Boosts Global CDMO Expansion
aju press South Korea Overview South Korea's leading biotech firms, Samsung Biologics and Celltrion, show divergent paths: Samsung Biologics achieved record Q1 2026 performance with 25.8% revenue growth due to full plant utilization but ... -
Swiss Biotech Bioscibex Begins Shipments of Novel SW1NGO Single-Use Bioreactor-Incubators, Streamlining Bioprocess Seed Trains
Startupticker.ch Switzerland Overview Swiss biopharmaceutical startup Bioscibex has begun delivering its innovative SW1NGO single-use bioreactor-incubators to initial customers, marking a significant milestone. This system is designed to... -
Aldevron and Minaris Renew Lentiviral Plasmid Agreement, Bolstering Critical Supply for Advanced Cell and Gene Therapies
BioBuzz USA Overview Aldevron and Minaris have renewed their lentiviral plasmid licensing agreement, significantly expanding access to scalable plasmid solutions essential for advanced cell and gene therapy (CGT) developers. This collabo... -
CDMO Sector Sees Strategic Expansions: Andelyn Biosciences Launches LVV Platform, Made Scientific Partners with RoosterBio
DCAT Value Chain Insights USA Overview The biopharmaceutical contract development and manufacturing (CDMO) sector is experiencing significant strategic advancements, with Andelyn Biosciences unveiling its 'LVV curator platform' for stand... -
Synthetic Small Molecule API Market to See Growth through 2035, Driven by Oncology Pipeline and Generic Demand, Report Says
IndexBox Global Overview This article provides an overview of a market research report published by IndexBox, which forecasts growth in the global synthetic small molecule API market, driven by increasing chronic disease prevalence, a ro... -
Contract Organizations’ Pivotal Role in Lentiviral Manufacturing Accelerates Gene Therapy Commercialization
MAI CDMO Global Overview This article highlights the essential role of Contract Development and Manufacturing Organizations (CDMOs) in lentiviral vector manufacturing, crucial for gene and cell therapies like CAR-T. Lentiviral vector pro... -
U.S. Small Molecule API Market Forecast to Reach USD 103.37 Billion by 2035, Driven by HPAPI and Domestic Manufacturing
Precedence Research USA Overview This article presents an overview of a market research report published by Precedence Research, which projects the U.S. small molecule API market to reach USD 103.37 billion by 2035. Key growth drivers in... -
Silexion Therapeutics Initiates GMP Manufacturing for KRAS-Driven Cancer siRNA Therapy SIL204, Secures Phase 2/3 Trial Approval
Manila Times (via GlobeNewswire) ケイマン諸島 Overview Silexion Therapeutics has commenced GMP clinical batch manufacturing for SIL204, its next-generation siRNA therapeutic targeting mutated KRAS oncogenes. Concurrently, the company rec... -
Viral Vector Manufacturing Market Projected to Reach USD 12.84 Billion by 2036: Driven by Gene Therapy Advances and CDMO Role
OpenPR Global Overview This article provides an overview of a market research report distributed by OpenPR. The report forecasts that the global viral vector manufacturing market will reach USD 12.84 billion by 2036, driven by the increa...
